Evidence map›Paper›PMID 36548215›Full record

ArticleChemical research in toxicology2023

ZIM, a Norbornene Derived from 4-Aminoantipyrine, Induces DNA Damage and Cell Death but in Association Reduces the Effect of Commercial Chemotherapeutics.

Rodrigo Juliano Oliveira, Ingridhy Ostaciana Maia Freitas da Silveira, Silvia C das Neves, Barbara Mitsuyasu, Allana C Martins, Claudia Berno, Jiyan Mohammad, Halie Raj, Flavio H S de Araujo, Cristiane Regina Hortelan and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical research in toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Rodrigo Juliano OliveiraStem Cell, Cell Therapy and Toxicological Genetics Research Centre (CeTroGen), Medical School, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul79080-190, Brazil.
Ingridhy Ostaciana Maia Freitas da SilveiraInstitute of Chemistry, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul79070-900, Brazil.
Silvia C das NevesStem Cell, Cell Therapy and Toxicological Genetics Research Centre (CeTroGen), Medical School, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul79080-190, Brazil.
Barbara MitsuyasuDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota58102, United States.
Allana C MartinsDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota58102, United States.
Claudia BernoStem Cell, Cell Therapy and Toxicological Genetics Research Centre (CeTroGen), Medical School, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul79080-190, Brazil.
Jiyan MohammadDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota58102, United States.
Halie RajDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota58102, United States.
Flavio H S de AraujoStem Cell, Cell Therapy and Toxicological Genetics Research Centre (CeTroGen), Medical School, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul79080-190, Brazil.
Cristiane Regina HortelanInstituto Federal de Mato Grosso do Sul, Dourados, MSCEP 79833-520, Brazil.
Luana MachadoInstitute of Exact Sciences, Department of Chemistry, Federal University of Minas Gerais, Belo Horizonte, MGCEP 31270-901, Brazil.
Eufrânio N da Silva JúniorInstitute of Exact Sciences, Department of Chemistry, Federal University of Minas Gerais, Belo Horizonte, MGCEP 31270-901, Brazil.
Marcelo L B VilelaMedical School, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul79070-900, Brazil.
Valter Aragão NascimentoGraduate Program in Health and Development in the Midwest Region, Medical School, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul79070-900, Brazil.
Adilson BeatrizInstitute of Chemistry, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul79070-900, Brazil.ORCID 0000-0001-6864-6092
Roberto da Silva GomesDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota58102, United States.ORCID 0000-0002-8075-9716
Universidade Federal de Mato Grosso do Sul · BRNorth Dakota State University · USUniversidade Federal de Minas Gerais · BR

Funding

Targeting CLEC-2/podoplanin as a therapeutic strategy for pancreatic cancerP20GM109024 · NIGMS · NORTH DAKOTA STATE UNIVERSITY · PI Sanku Mallik · 2016 to 2026
$20.5M
NIGMS NIH HHS P20 GM109024
6 · The paper itself

Abstract

Cancer incidence is increasing, and the drugs are not very selective. These drugs cause adverse effects, and the cells become resistant. Therefore, new drugs are needed. Here, we evaluated the effects of

Indexed as

Antineoplastic AgentsCisplatinAmpyroneAnimalsCell DeathCyclophosphamideDNADNA DamageDoxorubicinMaleMiceMolecular Docking SimulationNorbornanesAmpyroneAntineoplastic AgentsCisplatinCyclophosphamideDNADoxorubicinNorbornanes

Identifiers

PMID36548215
PMCPMC12100995
OpenAlexW4312091566

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.